Overview of Cost-effectiveness Analysis

Gillian D Sanders^{1

2

3}, Matthew L Maciejewski^{1

4

5}, Anirban Basu⁶

Affiliations

¹ Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina.
² Duke Clinical Research Institute, Duke University, Durham, North Carolina.
³ Duke-Margolis Center for Health Policy, Duke University, Durham, North Carolina.
⁴ Durham Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT), Durham Veterans Affairs Health Care System, Durham, North Carolina.
⁵ Division of General Internal Medicine, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
⁶ The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Departments of Pharmacy, Health, Services and Economics, University of Washington, Seattle.

Gillian D Sanders et al. JAMA. 2019.

. 2019 Apr 9;321(14):1400-1401.

doi: 10.1001/jama.2019.1265.

Gillian D Sanders^{1

2

3}, Matthew L Maciejewski^{1

4

5}, Anirban Basu⁶

¹ Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina.
² Duke Clinical Research Institute, Duke University, Durham, North Carolina.
³ Duke-Margolis Center for Health Policy, Duke University, Durham, North Carolina.
⁴ Durham Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT), Durham Veterans Affairs Health Care System, Durham, North Carolina.
⁵ Division of General Internal Medicine, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
⁶ The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Departments of Pharmacy, Health, Services and Economics, University of Washington, Seattle.

No abstract available

Publication types